Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant human antibody to Human ERBB3. Duligotumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to HER3
Type
IgG
Species Reactivity
Human
Expression Host
CHO
Applications
Suitable for use in FC, IP, ELISA, Neut, FuncS, IF, WB and most other immunological methods.
CAS
1314238-96-4
Protein Construction
Patents refer to a Bispecific antibody Her3 / EGFR but duligotumab is described as solely anti-Her3 in INN entrygamma1 heavy chain (1-451) [Homo sapiens VH (IGHV3-74*01 (82.70%) – (IGHD) – IGHJ4*01) [8.8.14] (1-121) – IGHG1*03 CH1 R120>K (218) (122-451)], (224-214') – disulfide withkappa light chain (1'-214') [Homo sapiens V- KAPPA (IGKV1- 39*01 (87.40%) – IGKJ2*01 L124>V (104)) [6.3.9] (1'-107') – IGKC*01 (108'-214')];(230-230'':233-233'') – bisdisulfide dimer"Anti-HER3/EGFR, a dual action antibody, is a phage-derived, human IgG1 monoclonal antibody that is designed to target human epidermal growthfactor receptor 3 (HER3) and epidermal growth factor receptor (EGFR)." – Roche pipeline
Purity
>95.0% as determined by Analysis by RP-HPLC & analysis by SDS-PAGE.
BACKGROUND
Antigen Description
Receptor tyrosine-protein kinase erbB-3, also known as HER3 (human epidermal growth factor receptor 3), is a membrane bound protein that in humans is encoded by the ERBB3 gene.
Function
ATP binding; growth factor binding; growth factor binding; nucleotide binding; protein binding; protein heterodimerization activity; protein heterodimerization activity; protein homodimerization activity; protein tyrosine kinase activator activity; NOT pr